Second Sight Medical Products Inc
EYESW
NASDAQ Capital Market0.22
USD
+0.02
- -
CIK
0001266806
Return %
Stock
S&P500
1Y
-4.48
23.08
3Y
-94.78
67.59
5Y
-94.78
74.74
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- None
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- CA United States of America
- IPO Date
- Mar 29, 2017
- CIK
- 0001266806
- Similar Companies
- Business
- Second Sight Medical Products, Inc. (EYESW) develops, manufactures, and markets implantable visual prosthetics designed to provide artificial vision to blind individuals, including its commercially approved Argus II Retinal Prosthesis System for treating outer retinal degenerations such as retinitis pigmentosa; the system comprises an epiretinal implant, external camera and video processing unit; and the Orion Visual Cortical Prosthesis, a clinical-stage device targeting blindness from diverse causes like optic nerve disease, glaucoma, and trauma. Founded in 1998 and headquartered in Sylmar, California, the company previously operated geographically in the United States, Canada, Europe, the Middle East, Latin America, and Asia-Pacific through facilities including an office in Lausanne, Switzerland. In August 2022, Second Sight completed a reverse merger with Nano Precision Medical, Inc., resulting in a name change to Vivani Medical, Inc. (NASDAQ: VANI) where Second Sight holds approximately 23% ownership, shifting strategic focus to include miniaturized subdermal drug implants like NPM-119 for Type 2 diabetes while pursuing options for its visual prosthetics portfolio; in March 2025, Vivani announced plans to spin off its Cortigent subsidiary—formerly Second Sight—as a fully independent entity, with the spin-off distribution set for September 2025.